T1	Participants 86 123	advanced epithelial ovarian carcinoma
T2	Participants 946 997	A total of 226 patients were evaluable for response
T3	Participants 408 485	Patients with bidimensionally measurable disease were randomised to topotecan
T4	Participants 750 936	C30 questionnaire was also used to measure eight symptoms at baseline and during each course (pain, anorexia, diarrhoea, fatigue, nausea and vomiting, dyspnea, constipation and insomnia)
